As the NFL kicks off its 100th season, it's the biggest time of the year for fantasy football. FanDuel, the daily fantasy sports app, also now offers legal sports betting in six states: New York, New Jersey, Pennsylvania, West Virginia, Indiana, and Iowa. FanDuel CEO Matt King joins Yahoo Finance to discuss what to expect for fantasy betting in the upcoming season.
Johnson & Johnson CEO Alex Gorsky said the group "continues to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon."
Top news and what to watch in the markets on Tuesday, January 26, 2021.
Your retirement savings are $1 million. You want $100,000 of yearly retirement income, including Social Security. Is that doable without tons of risk?
GE said industrial cash flows for the 2021 year should rise to between $2.5 billion and $4.5 billion, delivering on a key commitment from CEO Larry Culp.
Millennials still love Tesla — it's their favorite S&P 500 stock — but they're actually making much more money on their five other top picks.
A mix of choices for investorsMutual funds can help diversify your retirement portfolio, whether you're looking for growth through equity exposure or dividend income. Vanguard has a reputation for offering low-cost index funds and exchange-traded funds to help investors achieve their retirement goals.
Johnson & Johnson earnings were better than expected, with the Dow giant also guiding higher for 2021. JNJ stock rose early Tuesday.
Shares of Verizon Communications Inc. were off 0.3% in premarket trading Tuesday despite fourth-quarter results that exceeded analyst expectations.
Goldman Sachs sounds the alarm on some very hot tech stocks.
Speaker Pelosi and other leaders want quick approval. How soon could you get more money?
There are still plenty of well-known companies paying dividends of 5% or more. Barron’s screened the S&P 500 index for high-yielding stocks and came up with 10 with yields of 5% to 9% based on data from S&P Dow Jones Indices. The nice thing about the 10 is that investors stand to get a recent return even if the stocks don’t appreciate much this year.
Raytheon beat fourth-quarter estimates Tuesday but gave mixed 2021 guidance amid expectations for a choppy recovery in aviation.
Growing concerns about stock bubbles on Wall Street are sparking fears of a pullback, highlighted by the wild ride for shares such as GameStop Corp. A flood of money supply, ultra-low or zero interest rates and COVID-19 vaccine rollouts have sparked a "buy everything" rally, helping world stocks add a whopping $33 trillion in value from their lows of last March. Surges in share prices of some loss-making firms, red-hot public markets and amateur investors chasing stocks have drawn concern as the benchmark S&P 500 has gained more than 70% since March.
The biotech sector has started the year with a bang. The industry benchmark, iShares NASDAQ Biotechnology ETF (IBB), is up ~11% so far in January -- far better than the S&P 500's 3% return. Covering the sector for Wells Fargo, 5-star analyst Jim Birchenough is upbeat about what he sees. “Overall, we see roughly 20% to 30% additional upside for the sector by historical metrics and would argue that accelerating pace of innovation and greater pipeline de-risking should ultimately support higher returns on investment,” Birchenough noted. An environment like that will be manna from heaven for any investor interested in pharmaceutical stocks; an improved political climate will just add some icing to this cake. “While a split House and Senate supporting continued legislative inertia would have been best received, in terms of maintaining a positive status quo for biotechnology growth, we believe that value proposition for emerging biotechnology therapeutics should win-out under any administration and House/Senate mix,” Birchenough added. With this in mind, we wanted to check out some of Wells Fargo's recent picks in the biotech space to see if the investment firm could steer us towards any game-changers. After running the tickers through TipRanks’ database, we found out that two recently scored Buy ratings from the rest of the Street, enough to earn a “Strong Buy” consensus rating. Karuna Therapeutics (KRTX) We will start with Karuna Therapeutics, a specialty pharma company whose focus is mental health. Specifically, Karuna works on the development of new drugs for the treatment of schizophrenia and dementia-related psychoses (DRP). With a potential patient base exceeding 2.7 million people, this is a large market. And the state of current treatment options is widely considered less than satisfactory. Medication side effects are severe, while therapeutic effects are less than desired. This leaves an opening for a company that can put a new, more effective, treatment on the market. Karuna is currently enrolling the pivotal Phase 3 EMERGENT-2 Study of its leading drug candidate, KarXT, for the treatment of acute psychosis in adults with schizophrenia. KarXT has showed a differentiated safety profile and efficacy in Phase 2 data. Furthermore, Phase 1b data in healthy elderly volunteers for DRP remain on track for 2Q21. This solid pipeline, with a new drug in multiple studies to treat several aspects of a serious disorder, has piqued Wells Fargo's interest. Covering KRTX for the firm, analyst Jacob Hughes writes, “Karuna Therapeutics is our top idea in 2021. While KRTX shares have had an impressive run... we see a very attractive setup for the stock over the next couple years and several important catalysts in 2021 to drive the shares higher… We think the pipeline has been de-risked and we like the risk/reward at these levels as the value of KarXT is proved out.” To this end, Hughes rates the stock an Overweight (i.e. Buy), and his $163 price target implies an upside of ~59% for the coming year. (To watch Hughes’ track record, click here) It’s not often that the analysts all agree on a stock, so when it does happen, take note. KRTX's Strong Buy consensus rating is based on a unanimous 6 Buys. The stock’s $138.80 average price target suggests a 35% upside from the current share price of $102.80. (See KRTX stock analysis on TipRanks) Zymeworks, Inc. (ZYME) Vancouver-based Zymeworks is a clinical stage biotech involved in researching new drugs for the treatment of cancer, autoimmune disorders, and inflammatory diseases. The company focuses on biotherapeutics, drugs precisely engineered for their target diseases. The company’s lead candidate, zanidatamab, has indications for biliary tract cancer, breast cancer, and gastroesophageal adenocarcinoma. The drug is in Phase 1/2 testing for these cancers. Zymeworks’ second clinical candidate, ZW49, like zanidatamab, is an HER2 bispecific antibody in early stage study as a solid tumor treatment. Initial data will be presented at an investor event on January 27. Based on Zymeworks’ recent study results, Wells Fargo’s Jim Birchenough writes, “[We] expect zanidatamab to differentiate from current HER2 standards by virtue of depth of response in both refractory and frontline patients and to attract a prominent partner to pursue neoadjuvant and adjuvant breast cancer studies, and for ZW49 go-forward dose to demonstrate consistent responses to support further development, with upside potential from additional dose escalation.” In line with his bullish stance, Birchenough rates ZYME an Overweight (i.e. Buy) and his price target, at $71, implies a ~47% growth ahead. (To watch Birchenough’s track record, click here) Turning now to the rest of the Street, it appears that other analysts are generally on the same page. With 4 Buys and 1 Hold assigned in the last three months, the consensus rating comes in as a Strong Buy. In addition, the $60.82 average price target implies ~26% upside from current levels. (See ZYME stock analysis on TipRanks) To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Investors who have owned stocks since 2016 generally have experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return in the past five years is 121.4%. But there is no question some big-name stocks performed better than others along the way. GE’s Trainwreck: One of the worst-performing, high-profile U.S. stocks of the past five years has been industrial giant General Electric Company (NYSE: GE). GE has been one of the blue chip stocks in the U.S. market for over a century and was one of the original Dow Jones Industrial Average components. But a difficult energy environment coupled with some questionable accounting, ill-timed investments and poor balance sheet management created a perfect storm for GE investors in recent years. At the beginning of 2016, GE shares were trading at around $30. They topped out at around $33 in mid-2016 and traded mostly above the $28 level through mid-2017. Then the bottom fell out. From that point, the stock plummeted ceaselessly for the next 18 months or so, as profits evaporated, growth stalled and the company slashed its dividend and reported major write-downs associated with its dubious past accounting practices. The stock eventually bounced at the $6.66 level in late 2018 on optimism that the worst of GE’s struggles were finally in the past. Related Link: Here's How Much Investing ,000 In Intel Stock 5 Years Ago Would Be Worth Today GE In 2021, Beyond: GE peaked at $13.26 prior to the COVID-19 pandemic sell-off, which pushed the stock back down to $5.48 in March, its low point of the past five years. GE has since rebounded to above $11. The company paid a $200 million settlement to the SEC in late 2020, seemingly closing the book on its accounting issues. GE investors that bought and held on through a volatile five-year period still took a huge hit. In fact, $1,000 worth of GE stock bought in 2016 would be worth about $454 today, assuming reinvested dividends. Looking ahead, analysts expect GE to continue to recover in the next 12 months. The average price target among the 17 analysts covering the stock is $13 suggesting 18.3% upside from current levels. See more from BenzingaClick here for options trades from BenzingaThis Day In Market History: Dow Hits Dot-Com Bubble Peak33 Blue Chip Companies That Are Suspending Campaign Donations After Capitol Insurrection© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
2020 was an absolutely unbelievable year for electric vehicle stocks, but with a new administration set to take the wheel, this year could be even bigger
Bank of America has high hopes for these tech stocks.Tech stocks have led the stock market higher for more than a decade.
With earnings turning around in 2021 and the stock making a notable move, is Ford primed for a comeback? Here’s what you should know.
Some companies favor a "do one job and do it well" approach. However, that is not the Sorrento Therapeutics (SRNE) way. While being laser-focused on just one objective can have its advantages, having a wider-based remit can be just as effective, if done well. That is certainly the opinion of Alliance Global analyst James Molloy when evaluating Sorrento’s prospects. “SRNE combines one of the most active and promising pipelines in the COVID space with a potentially transformative non-opioid pain pipeline, and adds in a deep oncology pipeline,” the analyst said. “Most of SRNE's pipeline has significant catalysts over the next 1-4 quarters, with multiple late-stage clinical data read-outs and multiple potential Emergency Use Authorization (EUA) launches as well.” So, what’s on offer from the Sorrento menu in the near-term? The company has already filed an EUA for COVI-STIX, a 15-minute nasal swab antigen test for SARS-CoV-2, in the US and Mexico, and the test could be launched as early as 1H21. Accurate COVID tests are still needed in the US and around the globe, and Molloy expects the assay to gain EUA approval and could “rapidly approach $500M in sales as soon as 2022.“ SRNE's 8-minute SARS-CoV-2 antibody test COVID-TRACK could swiftly follow in its footsteps with an EUA anticipated to be filed in the year’s first half, too. “This could easily be another $500million+ near term opportunity,” Molloy said. Furthermore, the company’s two neutralizing antibody treatments, COVI-DROPS and COVI-AMG, against SARS-CoV-2, could be launched in 2022. Each of these, as well, have the potential to bring in more than $500 million in sales, according to the analyst The company’s non-opioid pain pipeline also has several late-stage catalysts. Fast tracked by the FDA, Phase 3 data for sciatica pain candidate SP-102 should be available this year, while RTX for OsteoArthritis (OA) knee pain and intractable cancer pain will kick-off Phase 2 and Phase 3 studies, respectively, in 2021. Both target “substantial market opportunities.” Last but not least is Abivertinib, the company's oncology lead candidate, indicated for non-small-cell lung cancer (NSCLC) and B-cell lymphomas, and currently in Phase 3 trials in China with top line data anticipated in 1H21. To this end, based on the progress of the company's pipeline, Molloy sees significant gains in SRNE's future. The analyst rates the stock a Buy and his $35 price target implies a hefty 277% upside. (To watch Molloy’s track record, click here) Overall, Sorrneto currently has few, yet very positive analysts tracking its progress. With Buy ratings only – 3, in total - the stock has a Strong Buy consensus rating. There’s plenty of upside projected, too; At $28.67, the average price target suggests gains of ~209% over the next 12 months. (See SRNE stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The chip maker is scheduled to report fourth-quarter results Tuesday afternoon. Analysts expect the company to post sales of $3.02 billion, up 42% from a year ago.
Yahoo Finance